Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome

Sponsor
Tongji Hospital
Study ID
NCT06688838
Status
Enrolling By Invitation

Conditions

  • Blau Syndrome

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tofacitinib — DRUG
    If a patient does not respond well to DMARDs treatment, then Tofacitinib or TNFi treatment may be used instead.

Study Details

To investigate the effectiveness of the JAK 1/3 inhibitor tofacitinib in treating Blau syndrome and explore the association between various clinical and genetic features and therapeutic responses within the cohort.

Key Dates

Start date
Jan 1, 2017
Status verified
Jan 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
24 participants (estimated)

Arms

  • Arm: glucocorticoid+ DMARDs
    glucocorticoid+ DMARDs
  • Arm: glucocorticoid+TNFi
    glucocorticoid+TNFi
  • Arm: glucocorticoid+Tofacitinib
    glucocorticoid+Tofacitinib

Primary Outcome Measure

clinical responses [ Time Frame: through study completion, an average of 1 year ]

Related Studies